One of the frustrating things about medical research is the delay between when research is presented at a scientific meeting and when it actually gets to publication. Unfortunately, sometimes the gap is more than a year. For this reason, I trawl around the meeting abstracts which might have potential. One such meeting is the American Association of Cancer Research (AACR) concluding it's five-day Annual Meeting tomorrow. I am thrilled to report there are DIPG presentations at this meeting.
Here are the citations for the three presented abstracts:
1) Nathalene Truffaux, Ludivine Le Dret, Stephanie Puget, Gilles Vassal, Birgit Geoerger, Jacques Grill.
Activity of dasatinib and potential escape mechanisms in diffuse intrinsic pontine glioma (DIPG) models
In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; 2013 {Abstract 2763}
2) Sridevi Yadavilli, Madhuri Kambhampati, Oren J. Becher, Tobey MacDonald, Ravi Bellamkonda, Roger J. Packer, Javad Nazarian.
NG2 upregulation and its defective asymmetric distribution in pediatric brainstem glioma and diffuse intrinsic pontine glioma
In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; 2013. {Abstract 5004}
3) Marianne Hutt, Wendy Goldstein, Javad Nazarian, Antoinette Price, Kah Jing Lim, Katherine Warren, Howard Chang, Charles Eberhart, Eric Raabe.
Targeting the Notch and mTOR pathways in diffuse intrinsic pontine glioma
In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; 2013. {Abstract 5049}
The first abstract is from the French researchers that have pioneered the way for biopsies. The second is from National Children's in DC, Duke and Emory/Georgia Institute of Technology. The third is from the Mid Atlantic DIPG Consortium (MADC). The MADC abstract appears to be an extension of the abstract we highlighted here on March 23this year.
As the abstracts are meant for a group of researchers, they are most definitely highly scientific. Here is one thing to take away- it is possible to establish cell lines from freshly biopsied DIPG material. The French group has been able to establish 12 lines in this way!
Showing posts with label Focus on Research. Show all posts
Showing posts with label Focus on Research. Show all posts
Tuesday, April 9, 2013
Tuesday, April 2, 2013
Focus On Researh- Xiao Nan Li
Dedicated to a special boy, Paul Alexander Coleman III, who is continuing to make an impact.....
Because of the trifecta of basic science hurdles- no tissue, no cell lines, no animal models- DIPG bench research has only recently begun. This has only been possible because of the efforts of a few individuals struggling to make the previously impossible possible- make animal models from an inoperable tumor. One of these pioneers- Xiao Nan Li MD, PhD (Baylor College of Medicine/Texas Children's Cancer Center).
Dr Li's interest is in the fields of cancer stem cells, experimental therapeutics and diagnostic markers with a particular focus on developing "clinically relevant animal models" for preclinical testing.
I first became aware of Dr Li when a fellow brain tumor parent sent her son's post-mortem specimen across the from the east coast to Texas to try to make a difference for medulloblastoma. The lab wasn't only interested in medulloblastoma. Dr Li has established more than 25 xenograft mouse models of several different pediatric brain tumors. At some time, a post mortem DIPG specimen was obtained and through the lab's work a door was unlocked for DIPG. Dr Li was able to establish a DIPG animal mouse model from this tissue and the scientific value of DIPG autopsy specimens skyrocketed.
Although the lab is interested in fighting all pediatric brain tumors there seems to have been a special focus on DIPG. Texas Children's has cell lines and thus became one of the initial members of the DIPG Pre-clincal consortium which is collaboratively working on rapid analysis of the cell lines and drug testing.
The lab has at least 5 different DIPG mouse xenografts that can be used for other types of research. One of these research endeavors is using oncolytic viruses in the DIPG mice he developed. Dr Xaio Nan Li will be presenting his work in a mouse model on eliminating therapy resistant DIPGs with an oncolytic virus at the DIPG Symposium in Cincinnati on May 3rd. A link to the grant executive summary funded by the Cure Starts Now is listed below.
This oncolytic virus research is exciting especially in light of the recent publication out of University of Alabama looking at this issue in pediatric gliomas. Although the publication is a different virus, the idea is essentially the same. Novel therapies are going to be needed to eliminate treatment resistent subpopulations while sparing normal tissue. Oncolytic virus have been one of the innovative treatment that might be a weapon in the future against DIPG as well as other gliomas and brain tumors.
References:
Neuro-Oncology Research Lab of Dr Xiao Nan Li
http://ccitonline.org/tccc_production_old/cancer-genomics-li/
Harnessing Autopsied DIPG Tumor Tissues for Orthotopic Xenograft Model Development in the Brain Stems of SCID mice- Grant Award Final Report
http://www.dtic.mil/cgi-bin/GetTRDoc?AD=ADA568355
Eliminating Therapy-Resistant Diffuse Intrinsic Pontine Gliomas with Oncolytic Picorna Virus SVV-001: an in vivo Study in Intra-brain Stem Xenograft Mouse Models- Grant Executive Summary
http://www.thecurestartsnow.org/_pdfs/grant_2011-11_texas.pdf
Pediatric glioma stem cells: biologic strategies for oncolytic HSV viral therapy.
Front Oncol. 2013;3:28. doi: 10.3389/fonc.2013.00028. Epub 2013 Feb 28.
http://www.ncbi.nlm.nih.gov/pubmed/234506
Because of the trifecta of basic science hurdles- no tissue, no cell lines, no animal models- DIPG bench research has only recently begun. This has only been possible because of the efforts of a few individuals struggling to make the previously impossible possible- make animal models from an inoperable tumor. One of these pioneers- Xiao Nan Li MD, PhD (Baylor College of Medicine/Texas Children's Cancer Center).
Dr Li's interest is in the fields of cancer stem cells, experimental therapeutics and diagnostic markers with a particular focus on developing "clinically relevant animal models" for preclinical testing.
I first became aware of Dr Li when a fellow brain tumor parent sent her son's post-mortem specimen across the from the east coast to Texas to try to make a difference for medulloblastoma. The lab wasn't only interested in medulloblastoma. Dr Li has established more than 25 xenograft mouse models of several different pediatric brain tumors. At some time, a post mortem DIPG specimen was obtained and through the lab's work a door was unlocked for DIPG. Dr Li was able to establish a DIPG animal mouse model from this tissue and the scientific value of DIPG autopsy specimens skyrocketed.
Although the lab is interested in fighting all pediatric brain tumors there seems to have been a special focus on DIPG. Texas Children's has cell lines and thus became one of the initial members of the DIPG Pre-clincal consortium which is collaboratively working on rapid analysis of the cell lines and drug testing.
The lab has at least 5 different DIPG mouse xenografts that can be used for other types of research. One of these research endeavors is using oncolytic viruses in the DIPG mice he developed. Dr Xaio Nan Li will be presenting his work in a mouse model on eliminating therapy resistant DIPGs with an oncolytic virus at the DIPG Symposium in Cincinnati on May 3rd. A link to the grant executive summary funded by the Cure Starts Now is listed below.
This oncolytic virus research is exciting especially in light of the recent publication out of University of Alabama looking at this issue in pediatric gliomas. Although the publication is a different virus, the idea is essentially the same. Novel therapies are going to be needed to eliminate treatment resistent subpopulations while sparing normal tissue. Oncolytic virus have been one of the innovative treatment that might be a weapon in the future against DIPG as well as other gliomas and brain tumors.
References:
Neuro-Oncology Research Lab of Dr Xiao Nan Li
http://ccitonline.org/tccc_production_old/cancer-genomics-li/
Harnessing Autopsied DIPG Tumor Tissues for Orthotopic Xenograft Model Development in the Brain Stems of SCID mice- Grant Award Final Report
http://www.dtic.mil/cgi-bin/GetTRDoc?AD=ADA568355
Eliminating Therapy-Resistant Diffuse Intrinsic Pontine Gliomas with Oncolytic Picorna Virus SVV-001: an in vivo Study in Intra-brain Stem Xenograft Mouse Models- Grant Executive Summary
http://www.thecurestartsnow.org/_pdfs/grant_2011-11_texas.pdf
Pediatric glioma stem cells: biologic strategies for oncolytic HSV viral therapy.
Front Oncol. 2013;3:28. doi: 10.3389/fonc.2013.00028. Epub 2013 Feb 28.
http://www.ncbi.nlm.nih.gov/pubmed/234506
Subscribe to:
Posts (Atom)